Lilly Eli & Co Stock Price, News & Analysis

Scribe Therapeutics announced its participation in the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, scheduled for May 13-17, 2025, in New Orleans. The company will present two significant developments: First, data on their X-Editor (XE) technology for treating Duchenne Muscular Dystrophy (DMD), showcasing its potential for inherited muscle disorders. Second, a joint presentation with Prevail Therapeutics, a Lilly subsidiary, demonstrating their collaboration on self-inactivating AAV vectors combined with CRISPR-based XE technology, which showed effective in vivo editing in mice's central nervous system. The companies recently achieved a milestone in their partnership focusing on neurological and neuromuscular diseases.

Eli Lilly (NYSE:LLY) announced its participation in the upcoming Bank of America Securities 2025 Healthcare Conference on May 15, 2025. The company's executive vice president and CFO, Lucas Montarce, will participate in a fireside chat at 11:40 a.m. Eastern time.

Investors can access a live audio webcast of the presentation through Lilly's investor website, with a replay available for approximately 90 days following the event.

Scribe Therapeutics has reached a success milestone in its collaboration with Prevail Therapeutics, a subsidiary of Eli Lilly (NYSE: LLY), for developing in vivo CRISPR-based therapeutics targeting neurological and neuromuscular disorders. This marks Scribe's second partnership achievement in 2025.

The companies will jointly present preclinical data on self-inactivating AAV (siXAAV) technology at the 28th ASGCT Annual Meeting in New Orleans. The presentation, focusing on CRISPR-CasX-Editor AAV vectors for CNS editing, is scheduled for May 15, 2025.

The collaboration, announced in 2023, includes potential payments of over $1.5 billion in milestones across all programs, plus low-double-digit royalties. The partnership leverages Scribe's CRISPR by Design™ approach and X-Editor technology platform alongside Prevail's expertise in neurological diseases.

Eli Lilly (NYSE: LLY) has scheduled its first-quarter 2025 financial results announcement for May 1, 2025. The company will host a conference call with investors, media, and the general public at 10 a.m. Eastern time to discuss the quarterly performance in detail.

A live webcast of the conference call will be accessible through Lilly's investor relations website, with a replay available after the event.

Eli Lilly (NYSE: LLY) announced positive Phase 3 results for orforglipron, the first oral small molecule GLP-1 receptor agonist to complete Phase 3 trials. The ACHIEVE-1 study demonstrated significant efficacy in treating type 2 diabetes, with A1C reductions of 1.3% to 1.6% from a baseline of 8.0% across doses.

Key findings include:

• At the highest dose (36mg), participants lost an average of 16.0 lbs (7.9%) in weight
• Over 65% of participants on the highest dose achieved A1C ≤6.5%
• Common side effects were gastrointestinal, including diarrhea (19-26%) and nausea (13-18%)

Lilly plans to submit orforglipron for weight management regulatory approval by end of 2025, with type 2 diabetes submission expected in 2026. The company confirms readiness for worldwide launch without supply constraints.

Kanvas Biosciences has published new research demonstrating the capabilities of its High-Phylogenetic-Resolution Spatial Mapping (HiPR-Map) Platform, a spectral imaging technology for microbiome analysis. The platform outperforms conventional sequencing methods with:

- Detection sensitivity of 0.01%
- Species-level microbial identification
- Single-nucleotide resolution of ribosomal RNA

The research revealed three key findings:

• Superior technical performance compared to traditional sequencing
• Detailed engraftment profiles of Live Biotherapeutic Products (LBPs) in mouse GI tract
• Comprehensive mapping of spatial microbial interactions at microscale and mesoscale levels

The technology aims to enhance LBP development for treating conditions ranging from colitis to various cancers, offering advantages over traditional fecal microbiota transplants (FMTs).

Eli Lilly (NYSE: LLY) announced positive Phase 2 results for lepodisiran, an investigational siRNA therapy targeting lipoprotein(a) [Lp(a)]. The ALPACA study demonstrated that lepodisiran reduced Lp(a) levels by 93.9% at the highest tested dose (400 mg) over 60-180 days, meeting its primary endpoint.

Key findings include:

• 16 mg dose achieved 40.8% reduction
• 96 mg dose achieved 75.2% reduction
• 400 mg dose maintained 91% reduction at 1 year
• 74.2% reduction persisted at 1.5 years

The treatment showed a favorable safety profile with minimal adverse events. About 20% of Americans have high Lp(a) levels, which can double or triple heart attack risk. The company is currently conducting the ACCLAIM-Lp(a) Phase 3 trial to evaluate cardiovascular outcomes in adults with elevated Lp(a).

Eli Lilly (LLY) has expanded its LillyDirect digital healthcare platform to improve access to Alzheimer's disease care in the U.S. through independent in-person and telehealth options. The expansion aims to address significant healthcare challenges, as the majority of the nearly 7 million Americans with Alzheimer's remain undiagnosed.

The platform now includes Healthgrades, a doctor locator tool for finding local clinicians experienced in Alzheimer's care, and Synapticure, an independent telehealth provider specializing in neurodegenerative care. Synapticure commits to connecting patients with care navigators within two days and neurologist appointments within two weeks.

This initiative addresses critical issues in Alzheimer's care, including:

• Wait times expected to exceed 1 year by 2025
• Nearly 1 in 5 Medicare beneficiaries traveling over 50 miles to see neurologists
• Approximately 3,000 Americans progressing daily from mild to moderate/severe stages